Symbols / CRVS
CRVS Chart
About
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.47B |
| Enterprise Value | 1.23B | Income | -15.07M | Sales | — |
| Book/sh | 0.96 | Cash/sh | 0.88 | Dividend Yield | — |
| Payout | 0.00% | Employees | 31 | IPO | — |
| P/E | — | Forward P/E | -29.15 | PEG | — |
| P/S | — | P/B | 18.20 | P/C | — |
| EV/EBITDA | -31.82 | EV/Sales | — | Quick Ratio | 8.18 |
| Current Ratio | 8.29 | Debt/Eq | 1.41 | LT Debt/Eq | — |
| EPS (ttm) | -0.54 | EPS next Y | -0.60 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-04 | ROA | -34.87% |
| ROE | -35.82% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 83.77M |
| Shs Float | 58.43M | Short Float | 21.54% | Short Ratio | 2.06 |
| Short Interest | — | 52W High | 26.95 | 52W Low | 2.54 |
| Beta | 0.75 | Avg Volume | 3.53M | Volume | 1.62M |
| Target Price | $33.33 | Recom | Strong_buy | Prev Close | $18.66 |
| Price | $17.49 | Change | -6.27% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$33.33
Mean price target
2. Current target
$17.49
Latest analyst target
3. DCF / Fair value
$-12.49
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$17.49
Low
$20.00
High
$51.00
Mean
$33.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-22 | main | Jefferies | Buy → Buy | $42 |
| 2026-01-21 | main | Oppenheimer | Outperform → Outperform | $32 |
| 2026-01-21 | main | Barclays | Overweight → Overweight | $28 |
| 2026-01-20 | main | HC Wainwright & Co. | Buy → Buy | $27 |
| 2025-10-13 | init | Barclays | — → Overweight | $16 |
| 2025-05-20 | main | Mizuho | Outperform → Outperform | $11 |
| 2025-05-09 | reit | Oppenheimer | Outperform → Outperform | $17 |
| 2025-03-26 | main | Oppenheimer | Outperform → Outperform | $15 |
| 2025-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-01-14 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-01-02 | init | HC Wainwright & Co. | — → Buy | $11 |
| 2024-11-13 | reit | Oppenheimer | Outperform → Outperform | $14 |
| 2024-09-16 | main | Ladenburg Thalmann | Buy → Buy | $21 |
| 2024-05-07 | main | Oppenheimer | Outperform → Outperform | $8 |
| 2024-04-01 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-03-27 | main | Mizuho | Neutral → Neutral | $4 |
| 2024-03-20 | main | Oppenheimer | Outperform → Outperform | $7 |
| 2023-09-07 | reit | Cantor Fitzgerald | Overweight → Overweight | $4 |
| 2023-06-16 | reit | Mizuho | Neutral → Neutral | $4 |
| 2023-05-30 | main | Ladenburg Thalmann | Buy → Buy | $10 |
- Is Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price Surge - Yahoo Finance ue, 17 Feb 2026 00
- Corvus Pharmaceuticals, Inc. $CRVS Shares Bought by GSA Capital Partners LLP - MarketBeat ue, 17 Feb 2026 12
- Corvus eczema drug improves key symptoms for 75% in early trial - Stock Titan ue, 20 Jan 2026 08
- Why Is CRVS Stock Rising Today? - Stocktwits ue, 20 Jan 2026 08
- Corvus Pharma stock falls after announcing $150 million offering - Investing.com ue, 20 Jan 2026 08
- Why Small Biotech Stock Corvus Pharma Just Launched To A Nine-Year High - Investor's Business Daily ue, 20 Jan 2026 08
- Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know (CRVS) - Seeking Alpha Wed, 21 Jan 2026 08
- Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know - Yahoo Finance ue, 27 Jan 2026 08
- Corvus Pharmaceuticals (CRVS) Valuation Check After A Sharp Biotech Share Price Surge - Sahm Mon, 09 Feb 2026 07
- Commit To Buy Corvus Pharmaceuticals At $8, Earn 20% Using Options - Nasdaq Mon, 02 Feb 2026 08
- Corvus Pharmaceuticals Stock Pre-Market (-5.9%): Announces $150M Public Offering - Trefis Wed, 21 Jan 2026 08
- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat Sun, 15 Feb 2026 07
- Corvus Pharma raises $201M to support cancer and skin trials - Stock Titan Fri, 23 Jan 2026 08
- CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million - Stocktwits Fri, 23 Jan 2026 08
- Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why - Yahoo Finance ue, 27 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1176332 | 4891894 | — | Sale at price 4.16 per share. | ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-27 00:00:00 | I |
| 1 | 1397684 | 4891894 | — | Conversion of Exercise of derivative security at price 3.50 per share. | ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-27 00:00:00 | I |
| 2 | 1176332 | 4891894 | — | Sale at price 4.16 per share. | THOMPSON PETER A | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-27 00:00:00 | I |
| 3 | 1397684 | 4891894 | — | Conversion of Exercise of derivative security at price 3.50 per share. | THOMPSON PETER A | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-27 00:00:00 | I |
| 4 | 19357 | 67750 | — | Conversion of Exercise of derivative security at price 3.50 per share. | JONES WILLIAM BENTON | Officer | — | 2025-06-04 00:00:00 | D |
| 5 | 559073 | 1956756 | — | Conversion of Exercise of derivative security at price 3.50 per share. | MILLER RICHARD A | Chief Executive Officer | — | 2025-05-07 00:00:00 | D |
| 6 | 302016 | — | — | Stock Gift at price 0.00 per share. | MILLER RICHARD A | Chief Executive Officer | — | 2024-05-10 00:00:00 | I |
| 7 | 577634 | 1000000 | — | Purchase at price 1.73 per share. | MILLER RICHARD A | Chief Executive Officer | — | 2024-05-06 00:00:00 | D |
| 8 | 20000 | 34624 | — | Purchase at price 1.73 per share. | JONES WILLIAM BENTON | Officer | — | 2024-05-06 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | 5.91M | -23.26M | -32.22M | -38.17M |
| TotalUnusualItems | -33.37M | 0.00 | 22.00K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -33.37M | 0.00 | 22.00K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -62.29M | -27.03M | -41.31M | -43.24M |
| ReconciledDepreciation | 85.00K | 151.00K | 367.00K | 460.00K |
| EBITDA | -27.46M | -23.26M | -32.20M | -38.17M |
| EBIT | -27.55M | -23.41M | -32.56M | -38.63M |
| NetInterestIncome | 1.82M | 1.58M | 654.00K | -15.00K |
| InterestExpense | 15.00K | |||
| InterestIncome | 1.82M | 1.58M | 654.00K | |
| NormalizedIncome | -28.92M | -27.03M | -41.33M | -43.24M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -62.29M | -27.03M | -41.31M | -43.24M |
| TotalExpenses | 27.55M | 23.41M | 32.56M | 38.63M |
| TotalOperatingIncomeAsReported | -27.55M | -23.41M | -32.56M | -38.63M |
| DilutedAverageShares | 60.99M | 48.03M | 46.55M | 41.85M |
| BasicAverageShares | 60.99M | 48.03M | 46.55M | 41.85M |
| DilutedEPS | -1.02 | -0.56 | -0.89 | -1.03 |
| BasicEPS | -1.02 | -0.56 | -0.89 | -1.03 |
| DilutedNIAvailtoComStockholders | -62.29M | -27.03M | -41.31M | -43.24M |
| NetIncomeCommonStockholders | -62.29M | -27.03M | -41.31M | -43.24M |
| NetIncome | -62.29M | -27.03M | -41.31M | -43.24M |
| NetIncomeIncludingNoncontrollingInterests | -62.29M | -27.03M | -41.31M | -43.24M |
| NetIncomeContinuousOperations | -62.29M | -27.03M | -41.31M | -43.24M |
| PretaxIncome | -62.29M | -27.03M | -41.31M | -43.24M |
| OtherIncomeExpense | -36.57M | -5.21M | -9.40M | -4.60M |
| OtherNonOperatingIncomeExpenses | 78.00K | 587.00K | 235.00K | |
| SpecialIncomeCharges | 5.00K | 0.00 | 22.00K | 0.00 |
| GainOnSaleOfPPE | 5.00K | 0.00 | 22.00K | 0.00 |
| EarningsFromEquityInterest | -3.20M | -5.28M | -10.01M | -4.83M |
| GainOnSaleOfSecurity | -33.38M | |||
| NetNonOperatingInterestIncomeExpense | 1.82M | 1.58M | 654.00K | -15.00K |
| TotalOtherFinanceCost | -1.58M | -654.00K | 15.00K | |
| InterestExpenseNonOperating | 15.00K | |||
| InterestIncomeNonOperating | 1.82M | 1.58M | 654.00K | |
| OperatingIncome | -27.55M | -23.41M | -32.56M | -38.63M |
| OperatingExpense | 27.55M | 23.41M | 32.56M | 38.63M |
| ResearchAndDevelopment | 19.39M | 16.53M | 24.47M | 29.11M |
| SellingGeneralAndAdministration | 8.16M | 6.88M | 8.10M | 9.52M |
| GeneralAndAdministrativeExpense | 8.16M | 6.88M | 8.10M | 9.52M |
| OtherGandA | 8.16M | 6.88M | 8.10M | 9.52M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 67.90M | 49.04M | 46.55M | 46.55M |
| ShareIssued | 67.90M | 49.04M | 46.55M | 46.55M |
| TotalDebt | 1.12M | 1.37M | 2.60M | 3.65M |
| TangibleBookValue | 32.57M | 38.68M | 56.12M | 97.16M |
| InvestedCapital | 32.57M | 38.68M | 56.12M | 97.16M |
| WorkingCapital | 19.00M | 21.09M | 32.91M | 61.62M |
| NetTangibleAssets | 32.57M | 38.68M | 56.12M | 97.16M |
| CapitalLeaseObligations | 1.12M | 1.37M | 2.60M | 3.65M |
| CommonStockEquity | 32.57M | 38.68M | 56.12M | 97.16M |
| TotalCapitalization | 32.57M | 38.68M | 56.12M | 97.16M |
| TotalEquityGrossMinorityInterest | 32.57M | 38.68M | 56.12M | 97.16M |
| StockholdersEquity | 32.57M | 38.68M | 56.12M | 97.16M |
| GainsLossesNotAffectingRetainedEarnings | -1.29M | -967.00K | -563.00K | 1.87M |
| OtherEquityAdjustments | -1.29M | -967.00K | -563.00K | 1.87M |
| RetainedEarnings | -397.01M | -334.72M | -307.69M | -266.38M |
| AdditionalPaidInCapital | 430.86M | 374.36M | 364.36M | 361.67M |
| CapitalStock | 7.00K | 5.00K | 5.00K | 5.00K |
| CommonStock | 7.00K | 5.00K | 5.00K | 5.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 36.34M | 6.87M | 12.12M | 12.29M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 937.00K | 0.00 | 1.37M | 2.60M |
| LongTermDebtAndCapitalLeaseObligation | 937.00K | 0.00 | 1.37M | 2.60M |
| LongTermCapitalLeaseObligation | 937.00K | 0.00 | 1.37M | 2.60M |
| CurrentLiabilities | 35.40M | 6.87M | 10.75M | 9.69M |
| OtherCurrentLiabilities | 29.20M | 245.00K | 158.00K | 121.00K |
| CurrentDebtAndCapitalLeaseObligation | 185.00K | 1.37M | 1.23M | 1.05M |
| CurrentCapitalLeaseObligation | 185.00K | 1.37M | 1.23M | 1.05M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 820.00K | 684.00K | 1.11M | 1.85M |
| PayablesAndAccruedExpenses | 5.20M | 4.57M | 8.25M | 6.68M |
| CurrentAccruedExpenses | 2.62M | 3.04M | 6.28M | 5.11M |
| Payables | 2.58M | 1.52M | 1.98M | 1.56M |
| AccountsPayable | 2.58M | 1.52M | 1.98M | 1.56M |
| TotalAssets | 68.91M | 45.55M | 68.24M | 109.45M |
| TotalNonCurrentAssets | 14.50M | 17.60M | 24.58M | 38.14M |
| OtherNonCurrentAssets | 632.00K | 89.00K | 129.00K | 236.00K |
| InvestmentsAndAdvances | 12.54M | 16.12M | 21.88M | 34.27M |
| LongTermEquityInvestment | 12.54M | 16.12M | 21.88M | 34.27M |
| InvestmentsinAssociatesatCost | 12.54M | 16.12M | 21.88M | 34.27M |
| NetPPE | 1.33M | 1.39M | 2.57M | 3.64M |
| AccumulatedDepreciation | -4.63M | -4.70M | -4.55M | -4.25M |
| GrossPPE | 5.95M | 6.08M | 7.12M | 7.89M |
| Leases | 2.08M | 2.08M | 2.08M | 2.08M |
| OtherProperties | 3.70M | 3.83M | 4.89M | 5.67M |
| MachineryFurnitureEquipment | 171.00K | 171.00K | 142.00K | 142.00K |
| BuildingsAndImprovements | 3.19M | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 54.41M | 27.96M | 43.66M | 71.31M |
| OtherCurrentAssets | 548.00K | 220.00K | 102.00K | 128.00K |
| PrepaidAssets | 1.68M | 524.00K | 626.00K | 1.19M |
| Receivables | 216.00K | 63.00K | 633.00K | 539.00K |
| DuefromRelatedPartiesCurrent | 588.00K | 507.00K | ||
| AccruedInterestReceivable | 141.00K | 37.00K | 45.00K | 32.00K |
| AccountsReceivable | 75.00K | 26.00K | 588.00K | 507.00K |
| CashCashEquivalentsAndShortTermInvestments | 51.96M | 27.15M | 42.30M | 69.45M |
| OtherShortTermInvestments | 43.22M | 14.53M | 29.14M | 5.99M |
| CashAndCashEquivalents | 8.74M | 12.62M | 13.16M | 63.46M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -25.42M | -23.97M | -27.29M | -36.72M |
| IssuanceOfCapitalStock | 16.41M | 7.84M | 0.00 | 60.94M |
| CapitalExpenditure | -34.00K | -269.00K | -5.00K | |
| EndCashPosition | 8.74M | 12.62M | 13.16M | 63.46M |
| BeginningCashPosition | 12.62M | 13.16M | 63.46M | 16.45M |
| ChangesInCash | -3.88M | -539.00K | -50.30M | 47.00M |
| FinancingCashFlow | 49.03M | 7.86M | 0.00 | 62.16M |
| CashFlowFromContinuingFinancingActivities | 49.03M | 7.86M | 0.00 | 62.16M |
| ProceedsFromStockOptionExercised | 32.62M | 12.00K | 0.00 | 1.22M |
| NetCommonStockIssuance | 16.41M | 7.84M | 0.00 | 60.94M |
| CommonStockIssuance | 16.41M | 7.84M | 0.00 | 60.94M |
| InvestingCashFlow | -27.48M | 15.54M | -23.28M | 21.56M |
| CashFlowFromContinuingInvestingActivities | -27.48M | 15.54M | -23.28M | 21.56M |
| NetInvestmentPurchaseAndSale | -27.49M | 15.57M | -23.03M | 21.57M |
| SaleOfInvestment | 42.63M | 62.62M | 43.16M | 30.92M |
| PurchaseOfInvestment | -70.12M | -47.05M | -66.19M | -9.36M |
| NetPPEPurchaseAndSale | 5.00K | -34.00K | -247.00K | -5.00K |
| SaleOfPPE | 5.00K | 0.00 | 22.00K | 0.00 |
| PurchaseOfPPE | 0.00 | -34.00K | -269.00K | -5.00K |
| OperatingCashFlow | -25.42M | -23.93M | -27.02M | -36.72M |
| CashFlowFromContinuingOperatingActivities | -25.42M | -23.93M | -27.02M | -36.72M |
| ChangeInWorkingCapital | -1.65M | -3.59M | 1.41M | -3.24M |
| ChangeInOtherCurrentLiabilities | -252.00K | -1.23M | -1.05M | 1.34M |
| ChangeInOtherCurrentAssets | -571.00K | 1.11M | 1.08M | -1.36M |
| ChangeInPayablesAndAccruedExpense | 812.00K | -4.03M | 878.00K | -2.42M |
| ChangeInAccruedExpense | -245.00K | -3.58M | 467.00K | -523.00K |
| ChangeInPayable | 1.06M | -451.00K | 411.00K | -1.90M |
| ChangeInAccountPayable | 1.06M | -451.00K | 411.00K | -1.90M |
| ChangeInPrepaidAssets | -1.59M | -8.00K | 581.00K | -277.00K |
| ChangeInReceivables | -49.00K | 562.00K | -81.00K | -507.00K |
| ChangesInAccountReceivables | -49.00K | 562.00K | -81.00K | -507.00K |
| StockBasedCompensation | 3.00M | 2.15M | 2.69M | 4.23M |
| AmortizationOfSecurities | -1.14M | -894.00K | -170.00K | 239.00K |
| DepreciationAmortizationDepletion | 85.00K | 151.00K | 367.00K | 460.00K |
| DepreciationAndAmortization | 85.00K | 151.00K | 367.00K | 460.00K |
| OperatingGainsLosses | 36.57M | 5.28M | 9.98M | 4.83M |
| EarningsLossesFromEquityInvestments | 3.20M | 5.28M | 10.01M | 4.83M |
| GainLossOnInvestmentSecurities | 33.38M | |||
| GainLossOnSaleOfPPE | -5.00K | 0.00 | -22.00K | 0.00 |
| GainLossOnSaleOfBusiness | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperations | -62.29M | -27.03M | -41.31M | -43.24M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CRVS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|